Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

15
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
15
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

12
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
12
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

12
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
12
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

13
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
13
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

18
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
18

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches: JACC: Heart Failure Position Statement.

JACC. Heart failure·2026
Same author

Persistent Disparities in Heart Failure: Looking Under the Hood of Social Determinants of Health, Adversity, and Biology.

JACC. Heart failure·2026
Same author

Association of Cannabis use and Survival in patients with heart failure: A claims-based cohort study of commercially insured adults.

American heart journal plus : cardiology research and practice·2026
Same author

Dilated Cardiomyopathy and Later Onset Limb-Girdle Muscular Dystrophy Associated With Fukutin and LaminA/C Mutations.

JACC. Case reports·2026
Same author

Editorial commentary: Cannabis and cardiovascular disease: Can we cut through the haze to clarify the risks and benefits?

Trends in cardiovascular medicine·2026
Same author

Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure.

European journal of heart failure·2025
Same journal

Guideline-Directed Medical Therapy Use and Dose Optimization after TAVR in Patients with Persistent HFrEF.

Journal of cardiac failure·2026
Same journal

Heart Failure Pharmacotherapy Across the TAVR Continuum.

Journal of cardiac failure·2026
Same journal

Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.

Journal of cardiac failure·2026
Same journal

Predictors and Outcomes of Heart Failure Diagnosis in the Community When Compared to Acute Care Settings: Insights from Linked Administrative Health Databases.

Journal of cardiac failure·2026
Same journal

Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration.

Journal of cardiac failure·2026
Same journal

What Are HFpEF Mimics and What Are They Mimicking? Insights Into Our Conceptualization of Heart Failure With Preserved Ejection Fraction as a Disease.

Journal of cardiac failure·2026
See all related articles

Related Experiment Video

Updated: Jul 11, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

3.7K

Nebulized Milrinone: Choosing Next Steps Wisely

Onyedika J Ilonze1, Peter S Pang2

  • 1Division of Cardiovascular Medicine, Indiana University School of Medicine, Indianapolis, IN.

Journal of Cardiac Failure
|November 12, 2023
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

505

Related Experiment Videos

Last Updated: Jul 11, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

3.7K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

505